Colorectal Dis. 2018 Feb;20(2):O46-O54. doi: 10.1111/codi.13997.
Closure of complex and contaminated abdominal wounds is challenging and carries risks, including wound dehiscence and incisional hernia. Hernia formation at closed stoma sites occurs in up to 30% of patients. Use of biological meshes in these situations may provide a safe method of reducing these complications, especially long-term incisional hernias.
The Reinforcement of Closure of Stoma Site (ROCSS) study is a Phase III multicentre randomized controlled trial (RCT) with an internal feasibility study. The primary objective of ROCSS is to assess whether a biological mesh (collagen tissue matrix) reduces the incidence of clinically detectable stoma closure site hernias at 2 years compared with standard closure techniques. Patients will be randomized in a 1:1 ratio to either standard suture (nonmesh) closure or closure with an intra-abdominal biological mesh reinforcement. Patients and outcome assessors are masked to treatment allocation. ROCSS aims to recruit 560 patients, with an option to recruit to 790 patients to increase power. The primary outcome measure is the occurrence of clinically detectable hernias years 2 years postrandomization. The secondary outcome measures are the radiological hernia rate at 1 year, incidence of symptomatic hernia, the surgical complication/re-intervention rate, quality of life, postoperative pain and cost-benefit analysis.
ROCSS is a multicentre RCT assessing the placement of a biological mesh at the site of stoma closure on clinical hernia rate. Our hypothesis is that reinforcing the stoma closure site with a collagen mesh is superior to the standard technique in reducing the risk of herniation at 2 years. These findings could influence future closure of stomas and other complex and/or contaminated abdominal wounds in settings around the world.
复杂污染腹部伤口的闭合具有挑战性,存在伤口裂开和切口疝等风险。在接受闭合造口的患者中,高达 30%会发生造口部位疝。在这些情况下使用生物补片可能是减少这些并发症的安全方法,尤其是长期切口疝。
Reinforcement of Closure of Stoma Site(ROCSS)研究是一项 III 期多中心随机对照试验(RCT),并包含内部可行性研究。ROCSS 的主要目的是评估生物补片(胶原组织基质)是否能降低 2 年时临床可检测的造口闭合部位疝的发生率,与标准闭合技术相比。患者将按 1:1 的比例随机分为标准缝线(非补片)闭合组或内置生物补片增强的闭合组。患者和结局评估者对治疗分组均设盲。ROCSS 旨在招募 560 例患者,可选择招募至 790 例患者以提高效能。主要结局指标是随机分组后 2 年时临床可检测的疝发生情况。次要结局指标是 1 年时的影像学疝发生率、症状性疝的发生率、手术并发症/再干预率、生活质量、术后疼痛和成本效益分析。
ROCSS 是一项多中心 RCT,评估了在造口闭合部位放置生物补片对临床疝发生率的影响。我们的假设是,用胶原补片增强造口闭合部位在降低 2 年时疝发生风险方面优于标准技术。这些发现可能会影响未来在世界各地的医疗机构中对造口和其他复杂及/或污染性腹部伤口的闭合。